<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476018</url>
  </required_header>
  <id_info>
    <org_study_id>Z100-02</org_study_id>
    <nct_id>NCT03476018</nct_id>
  </id_info>
  <brief_title>Trial to Optimally Show the Pharmacological Action of Z-100</brief_title>
  <official_title>Z-100 Pharmacological Trial: A Randomised Placebo-controlled Trial of Z-100 Plus Radiation Therapy in Subjects With Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeria Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to evaluate the change of the immunological parameter
      levels in FIGO stage IIIB cervical cancer subjects by administration of Z-100
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of immunological cells</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events/adverse drug reactions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 microgram Z-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 microgram Z-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>20 microgram Z-100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Z-100</intervention_name>
    <description>Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days</description>
    <arm_group_label>0.2 microgram Z-100</arm_group_label>
    <arm_group_label>2 microgram Z-100</arm_group_label>
    <arm_group_label>20 microgram Z-100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. FIGO stage (2008): IIIB, cervical cancer

          2. Pathologically confirmed squamous cell carcinoma of the cervix

          3. Subjects with treatment-naive cervical cancer

          4. Subjects without enlargement (≥15 mm in the short axis) in the lower abdominal
             para-aortic lymph node

          5. Subjects ≥21, ≤79 years of age at informed consent

          6. Subjects for whom it is considered possible to carry out intracavitary radiation in
             radiotherapy

          7. Subjects for whom it is considered possible to carry out concurrent cisplatin
             treatment with radiotherapy

          8. Eastern Cooperative Oncology Group Performance Status: 0-2

          9. Subjects with the following organ functions; (1) WBC ≥3,000/mm3 (2) Platelet count
             ≥100,000/mm3 (3) Hemoglobin ≥9.5 g/dL (correction by medication, e.g. blood
             transfusion, iron compounds, is allowed) (4) Total bilirubin ≤ three (3) times the
             upper limit of reference value at the clinical testing laboratory (5) AST, ALT ≤ three
             (3) times the upper limit of reference value at the clinical testing laboratory (6)
             Creatinine clearance: ≥50 mL/min

         10. Subjects who are willing to give informed consent

        Exclusion Criteria:

          1. Subjects who have a double cancer or are being treated for that

          2. Subjects who have suffered from cancers other than cervical cancer within 5 years
             prior to obtaining consent

          3. Subjects with cancer of the cervical stump which is judged by the investigator

          4. Subjects who have a history of being diagnosed of autoimmune disease

          5. Subjects who have a history of radiotherapy in the pelvis

          6. Subjects who have a history of hypersensitivity to cisplatin or other medical agents
             which contain platinum

          7. Subjects complicated with a serious drug allergy

          8. Subjects with a serious complication (poorly controlled hypertension, haemorrhagic
             tendency, connective tissue disease being treated with steroid)

          9. Pregnant women, nursing mothers or subjects who desire pregnancy during the trial
             period

         10. Subjects who have ongoing infection of human immunodeficiency virus (HIV), active
             hepatitis B virus (HBV), hepatitis C virus (HCV)

         11. Subjects with symptomatic tuberculosis at the date of obtaining consent

         12. Subjects who have received any other investigational medicinal products or medical
             devices within 28 days prior to obtaining consent

         13. Other subjects considered inappropriate to participate in the trial by the
             investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zeria R&amp;D</last_name>
    <phone>+81-3-5644-7053</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Zeria Investrigative Sites</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigative PIs</last_name>
      <phone>+81356447053</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zeria Investigative sites</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeria Investigative PIs</last_name>
      <phone>+81356447053</phone>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2018</study_first_submitted>
  <study_first_submitted_qc>March 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>March 17, 2018</last_update_submitted>
  <last_update_submitted_qc>March 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Specific substance maruyama</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

